Ginkgo Bioworks Holdings, Inc. (DNA) — 分析摘要
Ginkgo Bioworks Holdings, Inc.(DNA)的市值为541.54百万美元,最近一年的营收同比增长了-25.1%。净利润率为-183.8%。当前市盈率为-1.8倍。
核心要点
- 营收同比变化-25.1%
- 净利润率-183.8%
- 市盈率-1.8倍
与BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)板块的其他公司相比,DNA的营收增长为-25.1%,市盈率为-1.8倍。
Ginkgo Bioworks Holdings, Inc. (DNA)
更新 — ET · 来源 POLYGON
红旗与风险提示高风险信号
存在多项实质性红旗,在依赖任何估值输出前应先重点核查这些风险。
利息保障倍数为 -119.8x — 盈利不足以覆盖利息支出
营业利润率为 -210.7% — 严重经营亏损
净利率为 -215.4% — 亏损超过收入(可能含一次性费用)
营收较上一期下降 17.0%。
Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering engaged in providing biological R&D services for customers across a range of industries and Biosecurity that provides services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.
行业
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
员工人数
485
总部
BOSTON, MA
Exchange
XNYS
基于 4 年财务数据的系统性竞争优势评估
此评估基于历史财务数据的量化分析,不构成投资建议。护城河评级可能随行业和竞争环境变化。
首版展示近期 SEC Forms 3、4、5 备案活动。尚未解析单笔买入/卖出交易。
资本结构
现金流
免责声明:本站内容不构成投资建议。数据来源于SEC EDGAR和Polygon.io。过往业绩不代表未来表现。投资决策前请自行研究。